SCHEMBL25617618

SCHEMBL25617618

CCCN(CCOS(C)(=O)=O)c1ccc([N+](=O)[O-])cc1S(=O)(=O)N1CCN(Cc2cccnc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 2/20 0.40
POLB P06746 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.37
PKM P14618 1/20 0.37
CYP19A1 P11511 1/20 0.37
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
LMNA P02545 3/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25617560 0.93 ALDH1A1 (0.43) ALDH1A1CYP3A4CYP2C9CYP2C19KDM4E
SCHEMBL25617630 0.91 POLB (0.42) ALDH1A1CYP3A4CYP2C9CYP2C19KDM4E
SCHEMBL25617614 0.91 ALDH1A1 (0.51) ALDH1A1CYP3A4CYP2C9CYP2C19KDM4E
SCHEMBL25617815 0.89 ALDH1A1 (0.39) ALDH1A1CYP3A4CYP2C9CYP2C19KDM4E
SCHEMBL25617617 0.88 MAPT (0.39) ALDH1A1CYP3A4CYP2C9CYP2C19POLB
SCHEMBL25617612 0.87 ALDH1A1 (0.46) ALDH1A1CYP3A4CYP2C9CYP2C19KDM4E
SCHEMBL25617973 0.86 ALDH1A1 (0.37) ALDH1A1CYP3A4CYP2C9CYP2C19KDM4E
SCHEMBL25617620 0.85 ALDH1A1 (0.42) ALDH1A1CYP3A4CYP2C9CYP2C19KDM4E
SCHEMBL25617602 0.85 MAPT (0.48) ALDH1A1CYP3A4CYP2C9CYP2C19POLB
SCHEMBL25617510 0.85 ALDH1A1 (0.49) ALDH1A1CYP3A4CYP2C9CYP2C19KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661404-B2 Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders ACHILLES MEDICAL LIMITED (NZ) 2023-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661404-B2 Prodrug compounds activated by AKR1C3 and their use for treating hyperproliferative disorders AKR1C2, AKR1C1, AKR1B1 ALDH1A1 61/4885CYP3A4 263/4885CYP2C9 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.